Friday, October 30, 2026

Medical Properties Trust And 3 Other Stocks Have Very High Payout Ratio

ViaNews Editorial Team

September 20, 2023

Medical Properties Trust And 3 Other Stocks Have Very High Payout Ratio

(VIANEWS) - Medical Properties Trust (MPW), PIMCO Strategic Income Fund (RCS), Gilead Sciences (GILD) are the highest payout ratio stocks on this list.

Here's the data we've collected of stocks with a high payout ratio as yet. The payout ratio in itself isn't a guarantee of a future good investment but it's an indicator of whether dividends are being paid and how the company chooses to distribute them.

When investigating a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.

1. Medical Properties Trust (MPW)

1054.55% Payout Ratio

Medical Properties Trust, Inc. is a self-advised real estate investment trust formed in 2003 to acquire and develop net-leased hospital facilities. From its inception in Birmingham, Alabama, the Company has grown to become one of the world's largest owners of hospital real estate with 444 facilities and approximately 45,000 licensed beds in ten countries and across four continents. MPT's financing model facilitates acquisitions and recapitalizations and allows operators of hospitals to unlock the value of their real estate assets to fund facility improvements, technology upgrades and other investments in operations.

Earnings Per Share

As for profitability, Medical Properties Trust has a trailing twelve months EPS of $0.11.

PE Ratio

Medical Properties Trust has a trailing twelve months price to earnings ratio of 64.82. Meaning, the purchaser of the share is investing $64.82 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 0.84%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Medical Properties Trust's EBITDA is 10.16.

Sales Growth

Medical Properties Trust's sales growth is negative 3% for the ongoing quarter and negative 11.3% for the next.

Moving Average

Medical Properties Trust's value is way below its 50-day moving average of $8.90 and way under its 200-day moving average of $9.92.

Volume

Today's last reported volume for Medical Properties Trust is 7129030 which is 40.59% below its average volume of 12001000.

2. PIMCO Strategic Income Fund (RCS)

244.8% Payout Ratio

PIMCO Strategic Global Government Fund, Inc. is a closed-ended fixed income mutual fund launched and managed by Allianz Global Investors Fund Management LLC. The fund is co-managed by Pacific Investment Management Company LLC. It invests in fixed income markets across the globe. The fund primarily invests in government securities, including bonds issued or guaranteed by the United States or foreign governments, by their agencies, authorities or instrumentalities, or by supranational entities. It employs fundamental analysis with a focus on top down stock picking approach to create its portfolio. PIMCO Strategic Global Government Fund, Inc. was formed on February 24, 1994 and is domiciled in the United States.

Earnings Per Share

As for profitability, PIMCO Strategic Income Fund has a trailing twelve months EPS of $0.25.

PE Ratio

PIMCO Strategic Income Fund has a trailing twelve months price to earnings ratio of 22.2. Meaning, the purchaser of the share is investing $22.2 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.38%.

3. Gilead Sciences (GILD)

68.05% Payout Ratio

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Merck & Co, Inc. and Tentarix Biotherapeutics Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Earnings Per Share

As for profitability, Gilead Sciences has a trailing twelve months EPS of $4.35.

PE Ratio

Gilead Sciences has a trailing twelve months price to earnings ratio of 17.43. Meaning, the purchaser of the share is investing $17.43 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 26.35%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 5.4%, now sitting on 27.38B for the twelve trailing months.

4. Banner Corporation (BANR)

31.89% Payout Ratio

Banner Corporation operates as the bank holding company for Banner Bank that provide commercial banking and financial products and services to individuals, businesses, and public sector entities in the United States. It accepts various deposit instruments, including interest-bearing and non-interest-bearing checking accounts, money market deposit accounts, regular savings accounts, and certificates of deposit, as well as treasury management services and retirement savings plans. The company also provides commercial real estate loans, including owner-occupied, investment properties, and multifamily residential real estate loans; construction, land, and land development loans; residential mortgage loans; commercial business loans; agricultural loans; and consumer and other loans, such as home equity lines of credit, automobile, and boat and recreational vehicle loans, as well as loans secured by deposit accounts. In addition, it engages in the mortgage banking operations through the origination and sale of one-to four-family and multi-family residential loans, as well as small business administration loans. Further, the company provides electronic and digital banking services. As of December 31, 2021, it operated 150 branch offices and 18 loan production offices located in Washington, Oregon, California, Idaho, and Utah. Banner Corporation was founded in 1890 and is headquartered in Walla Walla, Washington.

Earnings Per Share

As for profitability, Banner Corporation has a trailing twelve months EPS of $5.77.

PE Ratio

Banner Corporation has a trailing twelve months price to earnings ratio of 7.54. Meaning, the purchaser of the share is investing $7.54 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.12%.

1. 1 (1)

1% Payout Ratio

1

Earnings Per Share

As for profitability, 1 has a trailing twelve months EPS of $1.

PE Ratio

1 has a trailing twelve months price to earnings ratio of 1. Meaning, the purchaser of the share is investing $1 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, 1's stock is considered to be overbought (>=80).

Earnings Before Interest, Taxes, Depreciation, and Amortization

1's EBITDA is 1.

In this story · Knowledge Files

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com